T1	p 177 183	breast
T2	p 326 341	breast cancer .
T3	p 471 513	patients receiving chemotherapy for breast
T4	p 827 875	chemotherapy-na?ve patients with breast cancer .
T5	p 1108 1157	. Median age of the 94 women was 51 years ( range
T6	p 1237 1297	doxorubicin/cyclophosphamide . Thirteen withdrew pre-cycle 2
T7	p 1486 1492	had no
T8	i 32 50	placebo-controlled
T9	i 115 128	dexamethasone
T10	i 151 172	adjuvant chemotherapy
T11	i 309 321	chemotherapy
T12	i 364 377	dexamethasone
T13	i 490 502	chemotherapy
T14	i 538 567	with dexamethasone or placebo
T15	i 762 782	dexamethasone ( 4 mg
T16	i 789 794	daily
T17	i 806 807	)
T18	i 815 822	placebo
T19	i 827 845	chemotherapy-na?ve
T20	i 910 956	granisetron and dexamethasone pre-chemotherapy
T21	i 961 977	oral granisetron
T22	i 1180 1227	fluorouracil/epirubicin/cyclophosphamide and 15
T23	i 1237 1265	doxorubicin/cyclophosphamide
T24	i 1374 1391	preferred placebo
T25	i 1467 1480	dexamethasone
T26	i 1676 1694	dexamethasone . No
T27	i 1862 1886	dexamethasone or placebo
T28	i 1902 1925	adjuvant chemotherapy .
T29	o 85 100	quality of life
T30	o 266 293	delayed nausea and vomiting
T31	o 403 424	, anxiety/agitation ,
T32	o 429 440	indigestion
T33	o 600 621	nausea and vomiting ,
T34	o 637 660	quality of life ( QOL )
T35	o 1084 1090	of QOL
T36	o 1358 1368	preference
T37	o 1493 1503	preference
T38	o 1535 1584	intensity of vomiting , nausea , or time to onset
T39	o 1588 1598	vomiting .
T40	o 1617 1639	decrease in global QOL
T41	o 1695 1720	other symptom/QOL domains
T42	o 1801 1839	patient preference , QOL , or symptoms